癌症免疫疗法
荣耀
免疫疗法
医学
癌症
内科学
光学
物理
标识
DOI:10.1038/d41573-021-00034-6
摘要
Before there was PD1, there was IL-2. Can drug developers channel the effects of this pleiotropic cytokine to take back the lead? Before there was PD1, there was IL-2. Can drug developers channel the effects of this pleiotropic cytokine to take back the lead?
科研通智能强力驱动
Strongly Powered by AbleSci AI